aTyr Pharma Inc
NASDAQ:ATYR

Watchlist Manager
aTyr Pharma Inc Logo
aTyr Pharma Inc
NASDAQ:ATYR
Watchlist
Price: 5.24 USD -8.23% Market Closed
Market Cap: 466.4m USD

Operating Margin
aTyr Pharma Inc

0%
Current
-7 372%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-67.1m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
aTyr Pharma Inc
NASDAQ:ATYR
466.4m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
330.5B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.4B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
137.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
127.8B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

aTyr Pharma Inc
Glance View

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel immunological pathways. The company is headquartered in San Diego, California and currently employs 49 full-time employees. The company went IPO on 2015-05-07. Its therapeutic candidate pipeline includes efzofitimod (ATYR1923), ATYR2810, NRP2 mAbs, AARS-1 and DARS-1. The ATYR1923, is a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the fragment crystallizable (Fc) region of a human antibody and serves as a selective modulator of NRP2 that downregulates innate and adaptive immune response in inflammatory disease states. The firm is also developing efzofitimod as a potential disease-modifying therapy for patients with fibrotic lung diseases with high unmet medical need. ATYR2810 is a fully humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and one of its primary ligands VEGF. ATYR2810 is in preclinical development for the potential treatment of certain aggressive cancers where NRP2 is implicated.

ATYR Intrinsic Value
7.39 USD
Undervaluation 29%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-67.1m
/
Revenue
0
What is the Operating Margin of aTyr Pharma Inc?

Based on aTyr Pharma Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top